Aria offers an attractive opportunity for investors to participate in an important area of research with the potential to introduce a transformational product for the treatment of AD.  Highlights of the opportunity include:


• A focused drug development effort with a pre-commercial exit strategy


• Novel, patented first-in-class drugs that address AD pathology with a novel mechanism of action:


• Reduction of Aβ formation, through post–transcriptional modulation of APP expression, a mechanism that in contrast to current strategies, does not involve secretase inhibition


• An experienced leadership team with a solid track record of drug development


• Clear exit strategy with multiple liquidity exits possible including upon identification of a Lead Development Candidate, IND filing, or human POC data availability


Worldwide sales of drugs to treat AD approximated $4.3 billion in 2012 (Nature, 2013). The AD drug market is forecast to experience double-digit growth to 2020. The catalysts for this growth include an aging population, earlier and improved diagnosis, and the introduction of therapies that can be prescribed in addition to existing treatments (Reuter’s 2012). Industry analysts believe a single new and truly effective AD drug could capture annual sales of over $10 billion dollars.


For corporate partnership or investment opportunities, please contact:


Dr. Bijan Almassian


Founder & Chairman


295 Washington Ave

Suite 4N, Hamden, CT 06518


(203) 815-5782



Aria Neurosciences, Inc.

295 Washington Ave, Suite 4N

Hamden, CT 06518

Tel:(203) 815-5782

Alzheimer's Disease

Copyright © 2013 Aria Neurosciences, Inc.